7 results on '"Rajkumar, S V"'
Search Results
2. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
- Author
-
Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, and Palumbo A
- Subjects
- Humans, Incidence, Multiple Myeloma epidemiology, Multiple Myeloma pathology, Neoplasms, Second Primary epidemiology, Risk Factors, Multiple Myeloma therapy, Neoplasms, Second Primary etiology
- Abstract
Background: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians., Design: A Panel of International Myeloma Working Group members reviewed the most relevant data published in the literature as full papers, or presented at meetings of the American Society of Clinical Oncology, American Society of Hematology, European Hematology Association, or International Myeloma Workshops, up to June 2016. Here, we present the recommendations of the Panel, based on this literature review., Results: Overall, the risk of SPMs in MM is low, multifactorial, and partially related to the length of patients' survival and MM intrinsic susceptibility. Studies suggest a significantly increased incidence of SPMs when lenalidomide is administered either following, or concurrently with, oral melphalan. Increased SPM incidence has also been reported with lenalidomide maintenance following high-dose melphalan, albeit to a lesser degree. In both cases, the risk of death from MM was significantly higher than the risk of death from SPMs, with lenalidomide possibly providing a survival benefit. No increase in SPM incidence was reported with lenalidomide plus dexamethasone (without melphalan), or with bortezomib plus oral melphalan, dexamethasone, or thalidomide., Conclusion: In general, the risk of SPMs should not alter the current therapeutic decision-making process in MM. However, regimens such as lenalidomide plus dexamethasone should be preferred to prolonged exposure to lenalidomide plus oral melphalan. SPM risk should be carefully discussed with the patient in the context of benefits and risks of different treatment options., (© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
3. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.
- Author
-
Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, and Winters JL
- Subjects
- Aged, Aged, 80 and over, Antibodies, Monoclonal urine, Female, Humans, Kidney Neoplasms pathology, Male, Middle Aged, Multiple Myeloma pathology, Renal Insufficiency etiology, Retrospective Studies, Treatment Outcome, Immunoglobulin Light Chains blood, Kidney Neoplasms complications, Multiple Myeloma complications, Plasma Exchange, Renal Insufficiency diagnosis, Renal Insufficiency therapy
- Abstract
Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting serum creatinine and dialysis independence. No baseline differences were noted between eventual renal responders and non-responders. Three quarters of the patients with biopsy proven cast nephropathy resolved their renal disease when the free light chains present in the serum were reduced by half or more but there was no significant response when the reduction was less. The median time to a response was about 2 months. In patients without cast nephropathy, renal recovery occurred despite reductions in free light chain levels of the serum. No association was found between free light chains in the serum, urinary monoclonal proteins, overall proteinuria and cast nephropathy. We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease.
- Published
- 2008
- Full Text
- View/download PDF
4. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.
- Author
-
Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, and Fonseca R
- Subjects
- Adult, Aged, Bone Marrow Cells pathology, Female, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, Plasma Cells pathology, Prevalence, Amyloidosis genetics, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 14, Immunoglobulin Heavy Chains genetics, Translocation, Genetic genetics
- Abstract
Primary systemic amyloidosis (AL) is a plasma cell (PC) dyscrasia with clinical similarities to multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS), but its molecular basis is poorly understood. Translocations at the immunoglobulin heavy-chain (IgH) locus, 14q32, are likely early genetic events in both MM and MGUS and involve several nonrandom, recurrent, partner chromosomes such as 11q13, 16q23, and 4p16.3. Given the similarities between MM, MGUS, and AL, bone marrow clonal PCs were evaluated in 29 patients with AL using interphase fluorescence in situ hybridization (FISH) combined with immunofluorescence detection of the cytoplasmic light-chain (cIg-FISH) for the presence of 14q32 translocations and the t(11;14)(q13;q32). Of 29 patients studied, 21 (72.4%) showed results compatible with the presence of a 14q32 translocation, and 16 (76.2%) of those had translocation (11;14)(q13;q32) for an overall prevalence of the abnormality of 55%. IgH translocations are common in AL, especially the t(11;14)(q13;q32).
- Published
- 2001
- Full Text
- View/download PDF
5. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia.
- Author
-
Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, and Tefferi A
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Histocytochemistry, Humans, Male, Microcirculation, Middle Aged, Multivariate Analysis, Neovascularization, Pathologic classification, Polycythemia Vera diagnosis, Polycythemia Vera physiopathology, Primary Myelofibrosis complications, Primary Myelofibrosis diagnosis, Prognosis, Prospective Studies, Risk Factors, Survival Rate, Thrombocythemia, Essential diagnosis, Thrombocythemia, Essential physiopathology, Bone Marrow blood supply, Neovascularization, Pathologic pathology, Primary Myelofibrosis physiopathology
- Abstract
Recent observations have underscored the biologic relevance of intratumoral angiogenesis and its potential impact on prognosis. Increased bone marrow angiogenesis has been demonstrated in a variety of hematologic disorders, including multiple myeloma. The extent and prognostic significance of bone marrow angiogenesis in 114 patients with myelofibrosis with myeloid metaplasia (MMM) was investigated. A control group of 44 patients without bone marrow disease, 15 patients with polycythemia vera, and 17 patients with essential thrombocythemia was also studied. Bone marrow microvessel density was assessed by a semiquantitative method, visual microvessel grading, and 2 separate quantitative methods, visual count and computerized image analysis. Angiogenesis estimation by all 3 methods was highly comparable. On visual microvessel grading, a grade 3 or 4 increase in bone marrow angiogenesis was demonstrated in 70% of patients with MMM, 33% of patients with polycythemia vera, 12% of patients with essential thrombocythemia, and 0% of normal controls. In a multivariate analysis, increased angiogenesis in MMM correlated significantly with increased spleen size and was found to be a significant and independent risk factor for overall survival. Increases in marrow angiogenesis correlated with hypercellularity and megakaryocyte clumping. In contrast, these 2 features were inversely proportional to reticulin fibrosis, whereas increases in marrow angiogenesis were independent of reticulin fibrosis. These preliminary findings suggest that neo-angiogenesis is an integral component of the bone marrow stromal reaction in MMM and may provide useful prognostic information and a rationale for the therapeutic investigation of anti-angiogenic agents.
- Published
- 2000
6. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
- Author
-
Rajkumar SV and Witzig TE
- Subjects
- Angiogenesis Inhibitors adverse effects, Angiogenesis Inhibitors pharmacology, Bone Marrow physiology, Cytokines pharmacology, Humans, Multiple Myeloma physiopathology, Thalidomide adverse effects, Thalidomide pharmacology, Angiogenesis Inhibitors therapeutic use, Multiple Myeloma drug therapy, Neovascularization, Pathologic physiopathology, Thalidomide therapeutic use
- Abstract
Angiogenesis is the formation of new blood vessels and occurs physiologically during embryonal growth, wound healing and during the menstrual cycle. It is essential for the proliferation and metastases of most malignant neoplasms. Recent evidence suggests that angiogenesis is increased in multiple myeloma and has prognostic value in the disease. Angiogenic cytokines such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor are expressed by myeloma cells and appear to play a role in the increased angiogenesis seen in myeloma. In addition, VEGF may serve as a paracrine growth factor for myeloma cells. Based on the increased angiogenesis observed in myeloma, thalidomide has been studied as antiangiogenic therapy. Although its mechanism of action in myeloma is still unclear, thalidomide appears to be active in 25-30% of patients with refractory myeloma. Major toxicities include constipation, sedation, skin rash, fatigue, and peripheral neuropathy. Studies are ongoing to determine its role as initial treatment for myeloma. This paper reviews the available data on angiogenesis in myeloma, and summarizes the role of thalidomide therapy in this disease. The pharmacology and toxicity of thalidomide are also discussed., (Copyright 2000 Harcourt Publishers Ltd.)
- Published
- 2000
- Full Text
- View/download PDF
7. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer.
- Author
-
Rajkumar SV and Adjei AA
- Subjects
- Alkaloids pharmacology, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Small Cell drug therapy, Carcinoma, Small Cell mortality, Deoxycytidine analogs & derivatives, Deoxycytidine pharmacology, Humans, Lung Neoplasms mortality, Survival Rate, Topoisomerase I Inhibitors, Vinblastine analogs & derivatives, Vinblastine pharmacology, Vinorelbine, Gemcitabine, Antineoplastic Agents therapeutic use, Lung Neoplasms drug therapy
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.